Wehrsdorf, Germany
- Featured
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
Phase
2Span
227 weeksSponsor
Mirati Therapeutics Inc.Gießen, Hessen
Recruiting
- Featured
Offenbach, Hessen
Recruiting
1-2 of 2